RhumbLine Advisers
NVO

RhumbLine Advisers’s Novo Nordisk NVO Stock Holding History

RhumbLine Advisers’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61M Sell
54,508
-231
-0.4% -$9.93K ﹤0.01% 1803
2026
Q1 		$2.01M Sell
54,739
-1,341
-2% -$63.5K ﹤0.01% 1861
2025
Q4 		$2.85M Sell
56,080
-1,302
-2% -$66.6K ﹤0.01% 1683
2025
Q3 		$3.18M Sell
57,382
-8,174
-12% -$478K ﹤0.01% 1650
2025
Q2 		$4.52M Buy
65,556
+2,017
+3% +$137K ﹤0.01% 1464
2025
Q1 		$4.41M Buy
63,539
+5,898
+10% +$487K ﹤0.01% 1421
2024
Q4 		$4.96M Sell
57,641
-5,598
-9% -$605K ﹤0.01% 1427
2024
Q3 		$7.53M Buy
63,239
+2,265
+4% +$302K 0.01% 1204
2024
Q2 		$8.7M Buy
60,974
+270
+0.4% +$35.8K 0.01% 1096
2024
Q1 		$7.79M Buy
60,704
+1,851
+3% +$220K 0.01% 1171
2023
Q4 		$6.09M Sell
58,853
-469
-0.8% -$46.4K 0.01% 1302
2023
Q3 		$5.39M Buy
59,322
+5,780
+11% +$509K 0.01% 1288
2023
Q2 		$4.33M Buy
+53,542
New +$4.37M ﹤0.01% 1463
2021
Q4 		– Sell
-4,180
Closed -$201K – 3018
2021
Q3 		$201K Buy
+4,180
New +$202K ﹤0.01% 2914
2016
Q3 		– Sell
-41,600
Closed -$1.12M – 2916
2016
Q2 		$1.12M Hold
41,600
– – ﹤0.01% 1714
2016
Q1 		$1.13M Hold
41,600
– – ﹤0.01% 1715
2015
Q4 		$1.21M Buy
41,600
+2,200
+6% +$60.9K ﹤0.01% 1686
2015
Q3 		$1.07M Buy
39,400
+1,200
+3% +$34K ﹤0.01% 1721
2015
Q2 		$1.05M Sell
38,200
-14,800
-28% -$416K ﹤0.01% 1836
2015
Q1 		$1.42M Sell
53,000
-200
-0.4% -$4.61K ﹤0.01% 1647
2014
Q4 		$1.13M Sell
53,200
-6,600
-11% -$147K ﹤0.01% 1721
2014
Q3 		$1.42M Hold
59,800
– – ﹤0.01% 1535
2014
Q2 		$1.38M Hold
59,800
– – ﹤0.01% 1621
2014
Q1 		$1.36M Sell
59,800
-1,000
-2% -$21.3K ﹤0.01% 1599
2013
Q4 		$1.12M Buy
60,800
+33,000
+119% +$575K ﹤0.01% 1735
2013
Q3 		$470K Buy
27,800
+10,000
+56% +$168K ﹤0.01% 2249
2013
Q2 		$276K Buy
+17,800
New +$296K ﹤0.01% 2720

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

RhumbLine Advisers's NVO Position: Q2 2026 in Review

RhumbLine Advisers reduced its Novo Nordisk (NVO) stake by 0.42% in Q2 2026, selling an estimated $9.93K and leaving 54,508 shares worth $2.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1803.

RhumbLine Advisers first reported a position in NVO in Q2 2013 and has held it in 27 quarters since. The position peaked at $8.7M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • RhumbLine Advisers held 54,508 shares of Novo Nordisk worth $2.61M as of Q2 2026.
  • RhumbLine Advisers sold 231 Novo Nordisk shares in Q2 2026, an estimated $9.93K.
  • Novo Nordisk made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1803 holding.
  • RhumbLine Advisers first reported a position in Novo Nordisk in Q2 2013 and has held it in 27 quarters since.
  • RhumbLine Advisers's Novo Nordisk position peaked at $8.7M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.